Issues related to intellectual property protection, enforcement, and market access within trade negotiations; supply chain management; China; Issues related to global health; and issues related to tariffs.
Source-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2026
- Income
- $90,000.00
- Expenses
- Not reported
- Registrant
- MONUMENT ADVOCACY
- Client
- PHRMA
- Filing UUID
- bdf08c5d-5af2-45f3-9ca5-7535942a2a36
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to intellectual property protection, enforcement, and market access within trade negotiations; supply chain management; China; issues related to global health; and issues related to tariffs.
Medicare Part D, Medicare Part B Issues, Importation of Drugs; H.R. 1, the One Big Beautiful Bill Act; H.R. 1492, S. 832, the EPIC Act; Medicare IRA implementation, Drug Premium Stabilization Program. Drug pricing, reimbursement and coverage related to MFN including CMMI models, 340B, IRA maximum fair price, ASP. PBM Reform included in H.R. 7194, the Consolidated Appropriations Act, the Department of Labor proposed PBM rule. Affordability and patient access issues; EPIC
Literal federal measure citations: H.R. 1, H.R. 1492, S. 832, H.R. 7194
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.